Vivoryon Therapeutics Showcases Breakthrough Results for DKD
Vivoryon Therapeutics N.V. Unveils Key Meta-analysis Results
Halle (Saale) / Munich, Germany – Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7), a pioneering clinical-stage biotechnology firm, is dedicated to developing innovative small molecule therapies targeting inflammatory and fibrotic disorders, particularly chronic kidney diseases. The company has shared pivotal meta-analysis data regarding its lead therapeutic candidate, varoglutamstat, at a significant educational congress.
Significant Presentation at Renowned Congress
At the recent congress of the European Renal Association, Vivoryon highlighted the positive outcomes from the Phase 2 trial program of varoglutamstat. CEO Frank Weber expressed profound excitement over presenting these findings, sharing that the improvements observed in kidney function (eGFR) demonstrated the potential of varoglutamstat to positively impact patients suffering from kidney diseases.
Key Findings from the Meta-analysis
According to the presentation, varoglutamstat, recognized as a first-in-class glutaminyl cyclase (QPCT/L) inhibitor, has shown remarkable anti-inflammatory and anti-fibrotic properties. The results from two independent Phase 2 studies—VIVIAD and VIVA-MIND—indicated a significant and clinically meaningful enhancement in kidney function among older patients. This correlation between treatment with varoglutamstat and improved eGFR was verified across both studies as well as through subsequent meta-analysis observations.
Clinical Implications of Results
The data illustrated that statistically noteworthy differences between varoglutamstat and placebo appeared as early as week 24 and continued to show sustained results up until week 96. Notably, participants with diabetes experienced an even greater effect size, a significant detail for the medical community working with diabetic patients.
Future Directions for Varoglutamstat
Looking ahead, Vivoryon plans to initiate a dedicated Phase 2b trial focusing on patients with diabetic kidney disease, specifically those with diabetes and chronic kidney disease classified as stage 3b/4. The trial aims to evaluate the efficacy of varoglutamstat on eGFR while exploring its impact on proteinuria and additional kidney-specific markers.
Presentation Overview and Details
The presentation occurred in Vienna, where Dr. Frank Weber discussed pivotal aspects of the study:
- Date: June 6, 2025
- Presentation Time: 8:15 am CEST
- Title: varoglutamstat improves eGFR and offers a new approach to treat diabetic kidney disease (DKD): meta-analysis from two independent Phase 2 studies
- Venue: Vienna, Austria
Company Background: Vivoryon Therapeutics N.V.
Vivoryon operates with an passionate vision to revolutionize treatments for inflammatory and fibrotic disorders affecting the kidney. With varoglutamstat being its flagship program, the company is committed to enhancing patient outcomes by altering the trajectory of severe kidney conditions through its innovative approaches in medicine.
Contact Details for Further Information
For inquiries, Vivoryon invites potential investors and interested parties to reach out to:
Investor Contacts
Dr. Manuela Bader, Director of Investor Relations & Communication
Email: [email protected]
LifeSci Advisors
Sandya von der Weid
Tel: +41 78 680 05 38
Email: [email protected]
Media Contact
Trophic Communications
Valeria Fisher or Verena Schossmann
Tel: +49 175 8041816 / +49 151 219 412 77
Email: [email protected]
Frequently Asked Questions
What is the main focus of Vivoryon Therapeutics?
Vivoryon Therapeutics primarily develops medicines targeting inflammatory and fibrotic kidney disorders.
What is varoglutamstat?
Varoglutamstat is an innovative QPCT/L inhibitor showing promise in improving kidney function.
What were the results of the recent studies presented?
The studies demonstrated significant improvements in kidney function among patients treated with varoglutamstat.
What are the next steps for Vivoryon?
The company plans to initiate a Phase 2b trial focusing on diabetic kidney disease.
How can interested parties contact Vivoryon?
Inquiries can be directed to the Investor Relations department via the provided email.
About The Author
Contact Owen Jenkins privately here. Or send an email with ATTN: Owen Jenkins as the subject to [email protected].
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.